Among the various material, poly (lactic-co-glycolic acid) (PLGA) is mainly used in the formation of sustained release microspheres due to its biodegradability, compatibility, and safety.
In this study, we confirmed the treatment ability of AMD, a diease which is caused by vascular endothelial growth factor (VEGF) signaling system, by using the PLGA sustained release of microspheres. The anti-VEGF drug, Rivoceranib was encapsulated through o/w single emulsion and solvent evaporation method with polymeric excipients PLGA.
In vivo study, the treatment of microspheres of PLGA/rivoceranib significantly inhibits the occurrence and spread of new blood vessels in the macular degeneration model. These results suggest that the treatment of sustained release microsphere with rivoceranib can be one strategy to treat the wet AMD through drug repositioning